Valuation: CSL Limited

Market Cap 46.34B 40.03B 37.61B 34.21B 64.31B 4,431B 65.37B 441B 172B 2,219B 174B 170B 7,374B P/E 2026 *
-51.8x
P/E 2027 * 32.3x
Enterprise Value 55.06B 47.55B 44.69B 40.64B 76.4B 5,265B 77.66B 524B 205B 2,636B 207B 202B 8,761B EV / Sales 2026 *
3.58x
EV / Sales 2027 * 3.48x
Free-Float
99.3%
Yield 2026 *
2.95%
Yield 2027 * 3.02%
1 day-0.74%
1 week+3.26%
Current month+10.92%
1 month+12.11%
3 months+39.34%
6 months-9.01%
Current year-20.94%
1 week 131.85
Extreme 131.85
139.03
1 month 113.75
Extreme 113.75
139.03
Current year 90
Extreme 90
184.62
1 year 90
Extreme 90
273.45
3 years 90
Extreme 90
313.55
5 years 90
Extreme 90
319.78
10 years 90
Extreme 90
342.75
Manager TitleAgeSince
Chief Executive Officer 63 2026-02-10
Director of Finance/CFO 52 2025-10-06
Chief Operating Officer - 2025-04-30
Director TitleAgeSince
Director/Board Member 72 2018-10-16
Director/Board Member 70 2011-02-01
Director/Board Member 71 2019-12-08
Date Insider Type Main position Quantity % Market Cap.
2/23/26 Free

Director

263 0.0001%
2/23/26 Free 512 0.0001%
2/19/26 Fiscal year

Director

183 0.0000%
Change 5-day change 1-year change 3-year change Capi.($)
-0.74%+3.26%-49.51%-49.96% 46.34B
-0.31%+2.44%+38.43%-0.30% 80.23B
-1.02%-0.51%-2.54%+26.80% 50.64B
-3.10%-4.84%+10.29%+158.34% 46.87B
-0.39%+0.91%+51.39%-22.35% 31B
-0.52%+7.01%+125.98%-34.32% 25.28B
-0.30%-0.33%+38.24%+83.70% 24.36B
-1.42%-1.11%-3.79%+190.40% 20.81B
-1.83%-2.82%+60.85%+107.54% 16.08B
-1.66%-5.47%+55.61%+162.18% 15.61B
Average -1.13%+0.75%+32.49%+62.20% 35.72B
Weighted average by Cap. -1.05%+0.84%+24.13%+42.38%

Financials

2026 *2027 *
Net sales 15.38B 13.28B 12.48B 11.35B 21.34B 1,471B 21.7B 146B 57.19B 736B 57.74B 56.49B 2,447B 15.59B 13.46B 12.65B 11.51B 21.63B 1,491B 21.99B 148B 57.96B 746B 58.53B 57.26B 2,481B
Net income -967M -835M -785M -714M -1.34B -92.44B -1.36B -9.19B -3.59B -46.29B -3.63B -3.55B -154B 1.18B 1.02B 961M 874M 1.64B 113B 1.67B 11.26B 4.4B 56.72B 4.45B 4.35B 188B
Net Debt 8.71B 7.53B 7.07B 6.43B 12.09B 833B 12.29B 82.88B 32.4B 417B 32.72B 32.01B 1,387B 7.98B 6.89B 6.47B 5.89B 11.07B 763B 11.25B 75.86B 29.66B 382B 29.95B 29.3B 1,269B
Logo CSL Limited
CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with approximately 325 plasma collection centers in the United States, Europe and China. The Company operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China (including Hong Kong). Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam, and others.
Employees
29,904
Date Price Change Volume
26-08-14 A$136.50 -0.74% 1,276,498
26-08-13 A$137.52 -0.66% 1,179,398
26-08-12 A$138.44 +0.08% 1,043,685
26-08-11 A$138.33 +2.87% 1,152,737
26-08-10 A$134.47 +1.72% 837,360
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
96.77USD
Average target price
97.30USD
Spread / Average Target
+0.55%

Quarterly revenue - Rate of surprise